Themis medicare is all set to enter the regulated markets soon. The company's product range in the CIS countries includes molecules and injectables
Themis Medicare will be launching molecules and injectables in the Commonwealth of Independent States (CIS). The company has already its presence in CIS through marketing tie-ups with the local firms and has already launched 10 to 12 products in these markets.
As part of its global expansion strategy, the company has already initiated steps for the upgradation of its manufacturing facility at Hyderabad. However, investment for the up gradation of the facility, which produces biotech products, mainly anti-cholesterol drugs, is yet to be decided.
The company with four state-of-the-art manufacturing facilities at three locations, in Vapi, Hyderabad and Haridwar, is one of the leading players in the active pharmaceutical ingredients (API) business in the domestic market. The company's manufacturing plants, situated in the industrial belts of Gujarat and Andhra Pradesh, conform to the international GMP standards. The plants are also approved by WHO-an acknowledgment of the good quality standards maintained by the plants.
Themis Medicare has an expanding international portfolio of affiliates across the globe with a presence in 40 countries. It is also planning to enter all 29 EU countries, USA, Canada, Australia with its unique research formulations in the future. A balanced geographical presence coupled with a strong product flow form a wide therapeutic range serves as the business building blocks of the company.
Its key focus areas are antituberculosis, antimalarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition. Themis is also engaged in co-marketing its research-based formulations with other pharmaceutical companies both in India and abroad.